Core Viewpoint - Organigram Global Inc. has received a recommendation from Institutional Shareholder Services Inc. (ISS) for shareholders to vote in favor of the acquisition of Sanity Group GmbH, citing strong strategic rationale and institutional confidence in the transaction [1][3]. Acquisition Details - The acquisition involves a combination of cash and Organigram shares valued at C$3.00 per share for Sanity shareholders, representing a 71.4% premium over the last unaffected trading price [4]. - The total upfront consideration for the acquisition is €113.4 million, consisting of €80.0 million in cash and €33.4 million in Organigram shares, with potential contingent earn-out consideration of up to €113.8 million based on Sanity's financial performance post-closing [4]. Strategic Rationale - ISS highlighted that the acquisition will provide increased scale, geographic diversification, improved market presence, a stronger balance sheet, and enhanced cash flow generation for the combined company [3]. - The transaction is supported by a private placement financing from British American Tobacco, Organigram's largest shareholder, indicating strong institutional confidence [3]. Market Reaction - Following the announcement, Organigram's shares experienced a positive market reaction, outperforming both the S&P/TSX Composite Index and the S&P/TSX Composite Pharmaceuticals Index [10]. - ISS noted that the favorable market reaction suggests elevated risk if the transaction is not approved [10]. Board Support - The Board of Directors of Organigram unanimously recommends that shareholders vote in favor of the transaction, having consulted with financial and legal advisors and received a fairness opinion confirming the financial fairness of the deal [5][10]. Meeting Matters - In addition to the acquisition vote, shareholders will also vote on the election of ten director nominees, the appointment of PricewaterhouseCoopers LLP as auditor, and the re-approval of unallocated awards under the Omnibus Equity Incentive Plan, with the Board recommending support for all these matters [6].

Core Insights - Organigram Global Inc. reported strong year-over-year growth in Q1 Fiscal 2026, driven by Canadian market leadership and increasing international sales, alongside improved gross margins [1][2] Financial Performance - Net revenue increased by 49% to $63.5 million from $42.7 million in Q1 Fiscal 2025, primarily due to contributions from the Motif Labs acquisition and higher international sales [1][2] - Adjusted gross margin rose to $23.9 million, or 38% of net revenue, compared to $14.3 million, or 33%, in Q1 Fiscal 2025, attributed to operational efficiencies and higher flower yields [1][2] - Adjusted EBITDA reached $5.3 million, a 273% increase year-over-year, driven by higher recreational and international revenue [1][2] Operational Highlights - The company harvested 28,645 kilograms, a 43% increase compared to Q1 Fiscal 2025, achieved through nutrient and environmental enhancements [1] - Organigram launched its Collective Project and Fetch brands into Illinois and Wisconsin, expanding its U.S. retail footprint to 11 states [1] - The company achieved a proprietary genetic screening breakthrough for powdery mildew resistance, significantly reducing identification time [1] Market Position - Organigram holds the 1 market share in Canada for vapes, milled flower, and concentrates, and ranks 2 in pre-rolls and 3 in edibles and dried flower [1] - International sales reached $5.0 million, a 51% increase year-over-year, with expectations for continued growth [1][2] Balance Sheet and Liquidity - As of December 31, 2025, the company had total cash of $63.0 million, with total assets amounting to $530.7 million [2] - Total liabilities decreased by 24% to $161.2 million, while shareholders' equity increased by 6% to $369.5 million [2]

Core Viewpoint - The rise and fall of Builder.ai exemplifies the dangers of narrative-driven investment in the AI sector, where the allure of technology often overshadows the reality of business practices and financial integrity [3][12]. Group 1: Company Background - Builder.ai was founded in 2016 by Sachin Dev Duggal, an engineer with a notable background, including early achievements in technology and entrepreneurship [4]. - The company initially positioned itself as a low-code development platform aimed at small and medium enterprises, promoting an AI assistant named "Natasha" as its technological core [5]. - Builder.ai attracted significant investment, including a $29.5 million Series A round led by SoftBank in 2018, and later secured $195 million in Series B funding in 2022 [6]. Group 2: Financial Misconduct - In 2024, internal audits revealed that Builder.ai had inflated its 2023 revenue by 20%-25%, leading to a drastic reduction in its 2024 revenue forecast from $220 million to $55 million [7]. - The company faced severe financial distress, culminating in its bankruptcy declaration in May 2025, with outstanding debts of $850 million to Amazon and $300 million to Microsoft [8]. - Allegations surfaced that Builder.ai had been misrepresenting its financial performance for years, with former employees claiming that the company had inflated sales figures by over 300% [8][9]. Group 3: Industry Implications - Builder.ai's collapse highlights a broader issue within the AI investment landscape, where the hype surrounding AI technologies often leads to a lack of due diligence among investors [12]. - The case draws parallels to other high-profile frauds in the tech industry, such as Theranos and Wirecard, indicating a pattern of misleading narratives attracting significant capital [10][11]. - The rapid growth of AI funding, which increased by 470% from 2020 to 2024, contrasts sharply with the low commercialization success rate of only 9%, suggesting a disconnect between investment enthusiasm and actual technological viability [12].

Core Viewpoint - The article discusses the emergence of a new health tech startup, Haemanthus, founded by Billy Evans, the partner of Elizabeth Holmes, the infamous figure behind the Theranos scandal. The company aims to innovate in health diagnostics while distancing itself from the Theranos legacy [3][4]. Group 1: Company Overview - Haemanthus is focused on animal testing and pet healthcare, with plans to expand into human diagnostics. The company was established in February 2024 and currently employs around ten staff members and several advisors, including veterinarians and diagnostic specialists [4]. - The startup has recently obtained its first patent for a small machine that uses laser technology to analyze blood, saliva, or urine samples for diseases such as cancer and infections [4][5]. Group 2: Funding and Investment Challenges - Haemanthus is seeking to raise $50 million (approximately 360 million RMB) for its operations and claims that product development will require three years and $70 million [6]. - Notable investors, including James W. Breyer and Michael Dell, have declined to invest in Haemanthus, citing concerns over the scientific validity and clinical applicability of the proposed technology [6][7]. Group 3: Background of Key Individuals - Billy Evans, the founder of Haemanthus, has a background in the hospitality industry and limited experience in biological diagnostics. His connection to Elizabeth Holmes raises concerns about the potential influence of her past on the new venture [10]. - Elizabeth Holmes, once celebrated as a visionary entrepreneur, is currently serving an 11-year prison sentence for fraud related to Theranos. Despite her incarceration, she continues to express ambitions to return to the biotech field post-release [11].

Core Viewpoint - The article discusses the emergence of a new health tech startup, Haemanthus, founded by Billy Evans, the partner of Elizabeth Holmes, who was convicted in the Theranos fraud case. The company aims to innovate in health diagnostics while distancing itself from the Theranos scandal. Group 1: Company Background - Haemanthus is focused on animal testing and pet healthcare, with plans to expand into human diagnostics. The company was established in February 2024 and currently employs around ten staff members and over twenty consultants, including veterinarians and diagnosticians [2]. - The company has recently obtained its first patent for a small box-shaped machine that uses laser technology to analyze blood, saliva, or urine samples for diagnosing diseases [3]. Group 2: Funding and Investment Challenges - Haemanthus is seeking to raise $50 million (approximately 360 million RMB) for its operations, having already secured several million dollars from family and friends [1]. - Notable investors, including James W. Breyer and Michael Dell, have declined to invest in Haemanthus, citing concerns over the scientific validity and clinical applicability of the proposed technology [4][5]. Group 3: Comparison with Theranos - The company’s product development timeline is projected to take three years and require $70 million, which raises skepticism among potential investors [4]. - Haemanthus's approach and product concept bear similarities to Theranos, particularly in its ambition to create a compact, wearable diagnostic device [4]. Group 4: Leadership and Team Concerns - The management team of Haemanthus includes members from Luminar, a struggling autonomous vehicle company, raising concerns about their experience in the health tech sector [9]. - Billy Evans, the founder, has a background in hospitality and limited experience in biotechnology, which has led to worries about his capability to lead a health tech startup [9].